NewsBenzinga바이오마린 파마슈티컬, 아센디스 파마와 라이선스 계약 체결···트랜스콘 CNP, 나베페그리타이드, 유비웰에 대한 라이선스 부여 및 2030년 5월까지 미국 20%, EU/브라질/한국 18% 로열티 지급 예정, 모든 소송 취하 바이오마린 파마슈티컬, 아센디스 파마와 라이선스 계약 체결···트랜스콘 CNP, 나베페그리타이드, 유비웰에 대한 라이선스 부여 및 2030년 5월까지 미국 20%, EU/브라질/한국 18% 로열티 지급 예정, 모든 소송 취하 Benzinga 2026.09.30 20:22 (GMT+0) Open on Benzinga Other news Piper Sandler Maintains Overweight on Halliburton, Lowers Price Target to $42 Eos Energy Enterprises Now Expects FY26 Revenue In Lower Half Of Its $300M To $350M Range CME Group Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call Dan Ives Says Meta, SpaceX and Tesla Face Big Questions This Week — His 3 'Big Focus Points' Ahead of Tech Earnings Mizuho Maintains Outperform on Equifax, Lowers Price Target to $185 NeuroSense Therapeutics Files U.S. Patent Application Covering Methods Of Treating Traumatic Brain Injury And Related Central Nervous System Injuries With Combination Of Ciprofloxacin And Celecoxib
CME Group Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Dan Ives Says Meta, SpaceX and Tesla Face Big Questions This Week — His 3 'Big Focus Points' Ahead of Tech Earnings
NeuroSense Therapeutics Files U.S. Patent Application Covering Methods Of Treating Traumatic Brain Injury And Related Central Nervous System Injuries With Combination Of Ciprofloxacin And Celecoxib